MK-801 PREVENTS THE ENHANCED BEHAVIORAL-RESPONSE TO APOMORPHINE ELICITED BY REPEATED ELECTROCONVULSIVE TREATMENT IN MICE

被引:14
|
作者
NOMIKOS, GG [1 ]
MATHE, AA [1 ]
MATHE, JM [1 ]
SVENSSON, TH [1 ]
机构
[1] ST GORANS UNIV HOSP, DEPT PSYCHIAT, S-10401 STOCKHOLM, SWEDEN
关键词
ELECTROCONVULSIVE TREATMENT; MK-801; APOMORPHINE; LOCOMOTOR ACTIVITY; DOPAMINE; NMDA RECEPTOR; MICE;
D O I
10.1007/BF02245125
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Repeated administration of electroconvulsive stimuli (ECS) to mice once daily for a period of 7 days results in an enhanced locomotor response induced by apomorphine (1.0 mg/kg, IP). Pretreatment (30 min) with the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 (0.01-1.0 mg/kg IP), suppressed ECS--induced seizure activity in a dose-dependent manner. MK-801 (0.01 and 0.033 mg/kg, IP) given 30 min before each ECS dose-dependently decreased apomorphine-mediated responses. Administration of MK-801 (0.033 mg/kg IP) 30 min after each convulsion had the same effect. These results indicate that MK-801 can abolish the ECS-induced enhancement of dopamine-mediated behaviour possibly by interfering with postictal processes. Thus, NMDA receptors seem to be involved in the behavioural changes and presumably also in the neural adaptations produced by repeated ECS.
引用
收藏
页码:367 / 370
页数:4
相关论文
共 45 条
  • [21] Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment
    Masoumeh Nozari
    Mohammad Shabani
    Mahdieh Hadadi
    Nafiseh Atapour
    Psychopharmacology, 2014, 231 : 4361 - 4370
  • [22] Effects of MK-801 and amphetamine treatments on allergic lung inflammatory response in mice
    Hamasato, Eduardo Kenji
    Ligeiro de Oliveira, Ana Paula
    Lino-dos-Santos-Franco, Adriana
    Ribeiro, Alison
    de Paula, Viviane Ferraz
    Schatzmann Peron, Jean Pierre
    Damazo, Amilcar Sabino
    Tavares-de-Lima, Wothan
    Palermo-Neto, Joao
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 16 (04) : 436 - 443
  • [23] ON THE ROLES OF DOPAMINE D-1 VS D-2 RECEPTORS FOR THE HYPERACTIVITY RESPONSE ELICITED BY MK-801
    MARTIN, P
    SVENSSON, A
    CARLSSON, A
    CARLSSON, ML
    JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1994, 95 (02) : 113 - 121
  • [24] The effects of citicoline and/or MK-801 on survival, neurological and behavioral outcome of mice exposed to transient hyperglycemia and oligemic hypoxia
    Rejdak, K
    Rejdak, R
    Sieklucka-Dziuba, M
    Stelmasiak, Z
    Grieb, P
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (05) : 333 - 341
  • [25] Effects of early postnatal MK-801 treatment on behavioral properties in rats: Differences according to treatment schedule
    Kawabe, Kouichi
    Miyamoto, Eri
    BEHAVIOURAL BRAIN RESEARCH, 2019, 370
  • [26] Behavioral and transcriptional effects of repeated electroconvulsive seizures in the neonatal MK-801-treated rat model of schizophrenia
    Lee, Jeonghoon
    Huh, Seonghoo
    Park, Kyungtaek
    Kang, Nuree
    Yu, Hyun Sook
    Park, Hong Geun
    Kim, Yong Sik
    Kang, Ung Gu
    Won, Sungho
    Kim, Se Hyun
    PSYCHOPHARMACOLOGY, 2024, 241 (04) : 817 - 832
  • [27] A dose-response analysis of the behavioral effects of (+)MK-801 in guinea pig: Comparison with CPP
    Jerram, AH
    Smith, PF
    Darlington, CL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1996, 53 (04) : 799 - 807
  • [28] Strain-dependent differential behavioral responses of zebrafish larvae to acute MK-801 treatment
    Liu, Xiuyun
    Guo, Ning
    Lin, Jia
    Zhang, Yinglan
    Chen, Xiao Qian
    Li, Sheng
    He, Lin
    Li, Qiang
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2014, 127 : 82 - 89
  • [29] Recapitulation of Neuropsychiatric Behavioral Features in Mice Using Acute Low-dose MK-801 Administration
    Mabunga, Darine Froy N.
    Park, Donghyun
    Ryu, Onjeon
    Valencia, Schley T.
    Adil, Keremlderoo Jym L.
    Kim, Seonmin
    Kwon, Kyoung Ja
    Shin, Chan Young
    Jeon, Se Jin
    EXPERIMENTAL NEUROBIOLOGY, 2019, 28 (06) : 697 - 708
  • [30] Enhanced interaction among ErbB4, PSD-95 and NMDAR by chronic MK-801 treatment is associated with behavioral abnormalities
    Li, Ji-Tao
    Feng, Yu
    Su, Yun-Ai
    Wang, Xiao-Dong
    Si, Tian-Mei
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2013, 108 : 44 - 53